Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annals of Surgical Oncology|July 7, 2025
The Landmark Series: Neoadjuvant Therapy for Resectable Pancreatic CancerChelsea F Cardell, Esther N Dekker, Matthew H G Katz, et al.
World Journal of Surgery|May 6, 2026
Contemporary Analysis of VTE Risk After HPB Surgery: 2517 Consecutive Patients Treated With Extended ChemoprophylaxisAnish J Jain, Esther N Dekker, Laura Prakash, et al.
The British Journal of Surgery|February 19, 2025
Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort studyEsther N Dekker, David van Klaveren, Eva M M Verkolf, et al.
Journal of the National Cancer Institute|March 20, 2026
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortiumEsther N Dekker, David van Klaveren, Eva M M Verkolf, et al.
The British Journal of Surgery|October 14, 2024
Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysisEsther N Dekker, Raja R Narayan, Mohamed A Ahmami, et al.
Annals of Surgical Oncology|February 5, 2025
Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 TrialEsther N Dekker, Quisette P Janssen, Jacob L van Dam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2024
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium StudyEsther N Dekker, Jacob L van Dam, Quisette P Janssen, et al.
Annals of Surgery|February 12, 2026
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized TrialIngmar F Rompen, Esther N Dekker, Thomas F Stoop, et al.
Annals of Surgery|August 12, 2025
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled TrialEsther N Dekker, Rutger T Theijse, Jacob L van Dam, et al.
European Journal of Cancer (Oxford, England : 1990)|July 14, 2026
Prognostic host phenotypes based on body composition and systemic inflammation predict survival in patients with resected pancreatic and periampullary cancerNicole D Hildebrand, David P J van Dijk, Jisce R Puik, et al.
Pageof 2